Synnovation Therapeutics

About | SynnovationTx

Wilmington, United States · Founded 2021 · $102.0M raised

Headquarters
Wilmington
Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$102.0M
Last Round
$102.0M Series AJan 2024
Rounds
1

About

Synnovation Therapeutics is a Wilmington, Delaware-based precision medicine company founded in 2021 by a world-class medicinal chemistry team from Incyte, where the founders previously contributed to the discovery of five approved drugs including Jakafi, Olumiant, Pemazyre, Tabrecta, and Opzelura. The company develops small-molecule targeted therapies optimized for best-in-class pharmacology against highly validated oncology targets. Its lead program, SNV1521, is a CNS-penetrant PARP1 inhibitor now in a Phase I study, and its second program targets oncogenic PI3K-alpha mutations. Synnovation launched publicly in January 2024 with a $102 million Series A led by Third Rock Ventures.

Summary

Synnovation Therapeutics is a Biotech company based in Wilmington, United States, founded in 2021. It has raised $102.0M in total across 1 round, most recently a $102.0M Series A round in Jan 2024. Investors include Third Rock Ventures, Nextech Invest and Lilly Asia Ventures.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJan 2024
$102.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Synnovation Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/synnovation-therapeutics"><img src="https://indexed.vc/api/badge/company/synnovation-therapeutics" alt="Synnovation Therapeutics on Indexed.vc" width="260" height="76" /></a>